This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vallisa, D. Articles by Cavanna, L. Search for Related Content PubMed PubMed Citation Articles by Vallisa, D. Articles by Cavanna, L. Social Bookmarking                            What's this?

Role of Anti-Hepatitis C Virus (HCV) Treatment in HCV-Related, Low-Grade, B-Cell, Non-Hodgkin's Lymphoma: A Multicenter Italian Experience

From the Department of Oncology and Hematology, G. da Saliceto Hospital, Piacenza; Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Paiva; Department of Oncology and Hematology, University of Modena, Modena; Haematology Division, Azienda Ospedaliera of Reggio Calabria, Reggio Calabria, Italy

Address reprint requests to Daniele Vallisa, MD, Department of Oncology and Hematology, G. da Saliceto Hospital, Piacenza, Via Taverna 49, 29100 Piacenza, Italy; e-mail: d.vallisa{at}ausl.pc.it

PURPOSE: Hepatitis C virus (HCV) is endemic in some areas of Northwestern Europe and the United States. HCV has been shown to play a role in the development of both hepatocellular carcinoma and B-cell non-Hodgkin's lymphoma (B-NHL). The biologic mechanisms underlying the lymphomagenic activity of the virus so far are under investigation. In this study, the role of antiviral (anti-HCV) treatment in B-NHL associated with HCV infection is evaluated.

PATIENTS AND METHODS: Thirteen patients with histologically proven low-grade B-NHL characterized by an indolent course (ie, doubling time no less than 1 year, no bulky disease) and carrying HCV infection were enrolled on the study. All patients underwent antiviral treatment alone with pegilated interferon and ribavirin. Response assessment took place at 6 and 12 months.

RESULTS: Of the twelve assessable patients, seven (58%) achieved complete response and two (16%) partial hematologic response at 14.1 ± 9.7 months (range, 2 to 24 months, median follow-up, 14 months), while two had stable disease with only one patient experiencing progression of disease. Hematologic responses (complete and partial, 75%) were highly significantly associated to clearance or decrease in serum HCV viral load following treatment (P = .005). Virologic response was more likely to be seen in HCV genotype 2 (P = .035), while hematologic response did not correlate with the viral genotype. Treatment-related toxicity did not cause discontinuation of therapy in all but two patients, one of whom, however, achieved complete response.

CONCLUSION: This experience strongly provides a role for antiviral treatment in patients affected by HCV-related, low-grade, B-cell NHL.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Paulli, L. Arcaini, M. Lucioni, E. Boveri, D. Capello, F. Passamonti, M. Merli, S. Rattotti, D. Rossi, R. Riboni, et al. Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT Ann. Onc., October 25, 2009; (2009) mdp454v1. [Abstract] [Full Text] [PDF]

				B Terrier, D Sene, D Saadoun, P Ghillani-Dalbin, V Thibault, A Delluc, J-C Piette, and P Cacoub Serum-free light chain assessment in hepatitis C virus-related lymphoproliferative disorders Ann Rheum Dis, January 1, 2009; 68(1): 89 - 93. [Abstract] [Full Text] [PDF]

				J. S. Abramson, M. Chatterji, and A. Rahemtullah Case 39-2008 -- A 51-Year-Old Woman with Splenomegaly and Anemia N. Engl. J. Med., December 18, 2008; 359(25): 2707 - 2718. [Full Text] [PDF]

				A. J. M. Ferreri, R. Dolcetti, M.-Q. Du, C. Doglioni, A. Giordano Resti, L. S. Politi, C. De Conciliis, J. Radford, F. Bertoni, E. Zucca, et al. Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy Ann. Onc., May 1, 2008; 19(5): 835 - 846. [Abstract] [Full Text] [PDF]

				C. S. Portlock, P. Hamlin, A. Noy, W. Chey, C. A. Gaydos, L. Palomba, I. Schwartz, S. Corcoran, L. Rosenzweig, D. Walker, et al. Infectious disease associations in advanced stage, indolent lymphoma (follicular and nonfollicular): developing a lymphoma prevention strategy Ann. Onc., February 1, 2008; 19(2): 254 - 258. [Abstract] [Full Text] [PDF]

				D. Saadoun, D. A. Landau, L. H. Calabrese, and P. P. Cacoub Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation Rheumatology, August 1, 2007; 46(8): 1234 - 1242. [Abstract] [Full Text] [PDF]

				L Arcaini, S Burcheri, A Rossi, M Paulli, R Bruno, F Passamonti, E Brusamolino, A Molteni, A Pulsoni, M. Cox, et al. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT Ann. Onc., February 1, 2007; 18(2): 346 - 350. [Abstract] [Full Text] [PDF]

				A. Ferreri, R Dolcetti, P Musto, G. Dognini, C Doglioni, and M Ponzoni Reply to the article 'Hepatitis C virus (HCV) infection and MALT-type ocular adnexal lymphoma (OAL)' by P. Arnaud, M.-C. Escande, M. Lecuit et al. (Ann Oncol doi:10.1093/annonc/mdl369) Ann. Onc., February 1, 2007; 18(2): 401 - 403. [Full Text] [PDF]

				D. Saadoun, J. Sellam, P. Ghillani-Dalbin, R. Crecel, J.-C. Piette, and P. Cacoub Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia. Arch Intern Med, October 23, 2006; 166(19): 2101 - 2108. [Abstract] [Full Text] [PDF]

				C Visco, L Arcaini, E Brusamolino, S Burcheri, A Ambrosetti, M Merli, E Bonoldi, M Chilosi, A Viglio, M Lazzarino, et al. Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy Ann. Onc., September 1, 2006; 17(9): 1434 - 1440. [Abstract] [Full Text] [PDF]

				L. Arcaini, M. Lazzarino, N. Colombo, S. Burcheri, E. Boveri, M. Paulli, E. Morra, M. Gambacorta, S. Cortelazzo, A. Tucci, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use Blood, June 15, 2006; 107(12): 4643 - 4649. [Abstract] [Full Text] [PDF]

				T. Yanagi, T. Shimizu, H. Ujiie, M. Ito, R. Abe, Y. Tsuji-Abe, S. Hige, and H. Shimizu Peginterferon alfa-2b for mycosis fungoides. Arch Dermatol, May 1, 2006; 142(5): 649 - 651. [Full Text] [PDF]

				A. J. M. Ferreri, E. Viale, M. Guidoboni, A. G. Resti, C. De Conciliis, L. Politi, A. A. Lettini, F. Sacchetti, R. Dolcetti, C. Doglioni, et al. Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa Ann. Onc., May 1, 2006; 17(5): 769 - 772. [Abstract] [Full Text] [PDF]

				F. Suarez, O. Lortholary, O. Hermine, and M. Lecuit Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation Blood, April 15, 2006; 107(8): 3034 - 3044. [Abstract] [Full Text] [PDF]

				M. de Jonge and J. Verweij The Epothilone Dilemma J. Clin. Oncol., December 20, 2005; 23(36): 9048 - 9050. [Full Text] [PDF]

				F. Bertoni and E. Zucca State-of-the-Art Therapeutics: Marginal-Zone Lymphoma J. Clin. Oncol., September 10, 2005; 23(26): 6415 - 6420. [Abstract] [Full Text] [PDF]

				C. Mazzaro, M. Spina, and U. Tirelli Regression of Low-Grade Non-Hodgkin's Lymphoma After Treatment With Pegylated Interferon Plus Ribavirin in Hepatitis C Virus Infection J. Clin. Oncol., July 1, 2005; 23(19): 4470 - 4471. [Full Text] [PDF]

				D. Vallisa, P. Bernuzzi, A. Lazzaro, E. Trabacchi, E. Anselmi, A. L. Arcari, C. Moroni, R. Berte, and L. Cavanna In Reply: J. Clin. Oncol., July 1, 2005; 23(19): 4471 - 4471. [Full Text] [PDF]

				E. Morra Cryoglobulinemia Hematology, January 1, 2005; 2005(1): 368 - 372. [Abstract] [Full Text] [PDF]